Protego Biopharma closed a $130 million oversubscribed Series B led by Novartis Venture Fund and Forbion to advance its first-in-class oral program for light‑chain (AL) amyloidosis into a potential pivotal study next year. The financing brings new and returning investors—Omega Funds, Droia Ventures and others—onto the cap table and extends the company’s runway for regulatory and manufacturing work. Protego’s oral stabilizer is positioned as an alternative to antibody therapies that failed in prior pivotal studies; the raise reflects investor appetite for differentiated oral approaches in rare protein‑misfolding diseases.